These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17502863)

  • 1. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes.
    Haider AS; Cardinale IR; Whynot JA; Krueger JG
    J Investig Dermatol Symp Proc; 2007 May; 12(1):9-15. PubMed ID: 17502863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor blockade: mechanism of action.
    Gottlieb AB
    J Investig Dermatol Symp Proc; 2007 May; 12(1):1-4. PubMed ID: 17502861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
    Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C
    J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit.
    Grundmann S; Hoefer I; Ulusans S; van Royen N; Schirmer SH; Ozaki CK; Bode C; Piek JJ; Buschmann I
    Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1497-505. PubMed ID: 15923311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
    Mitoma H; Horiuchi T; Hatta N; Tsukamoto H; Harashima S; Kikuchi Y; Otsuka J; Okamura S; Fujita S; Harada M
    Gastroenterology; 2005 Feb; 128(2):376-92. PubMed ID: 15685549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
    Wallis RS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):16-21. PubMed ID: 17502864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
    Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-target activity of TNF-alpha inhibitors characterized by protein biochips.
    Feyen O; Lueking A; Kowald A; Stephan C; Meyer HE; Göbel U; Niehues T
    Anal Bioanal Chem; 2008 Jul; 391(5):1713-20. PubMed ID: 18344017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro.
    Thaher F; Plankenhorn S; Klein R
    Int Immunopharmacol; 2011 Nov; 11(11):1724-31. PubMed ID: 21704732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage.
    Vuolteenaho K; Moilanen T; Hämäläinen M; Moilanen E
    Osteoarthritis Cartilage; 2002 Apr; 10(4):327-32. PubMed ID: 11950256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
    Harris J; Hope JC; Keane J
    J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.